[go: up one dir, main page]

ES2070926T3 - Supresion de la proliferacion celular mediante decorin. - Google Patents

Supresion de la proliferacion celular mediante decorin.

Info

Publication number
ES2070926T3
ES2070926T3 ES89730152T ES89730152T ES2070926T3 ES 2070926 T3 ES2070926 T3 ES 2070926T3 ES 89730152 T ES89730152 T ES 89730152T ES 89730152 T ES89730152 T ES 89730152T ES 2070926 T3 ES2070926 T3 ES 2070926T3
Authority
ES
Spain
Prior art keywords
decorin
cell proliferation
suppression
suppress
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89730152T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Yu Yamaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of ES2070926T3 publication Critical patent/ES2070926T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA DECORINA DE PROTEOGLICANO (TAMBIEN CONOCIDA COMO PG-II O PG-40). LA INVENCION PROPORCIONA CELULAS TRANSFERIDAS CON Y QUE EXPRESAN UN GENE QUE CODIFICA PARA DECORINA. LOS MEDIOS DE CULTIVO USADOS A PARTIR DE TALES CELULAS TRANSFERIDAS SE PUEDEN USAR PARA SUPRIMIR LA PROLIFERACION DE CELULAS NORMALES O ANORMALES. LA DECORINA PURIFICADA SE PUEDE USAR PARA SUPRIMIR LA PROLIFERACION DE CELULAS.
ES89730152T 1988-06-28 1989-06-24 Supresion de la proliferacion celular mediante decorin. Expired - Lifetime ES2070926T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21270288A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
ES2070926T3 true ES2070926T3 (es) 1995-06-16

Family

ID=22792114

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89730152T Expired - Lifetime ES2070926T3 (es) 1988-06-28 1989-06-24 Supresion de la proliferacion celular mediante decorin.

Country Status (11)

Country Link
US (2) US5726149A (es)
EP (1) EP0349480B1 (es)
JP (3) JP2887325B2 (es)
AT (1) ATE120235T1 (es)
AU (1) AU633011B2 (es)
CA (1) CA1340112C (es)
DE (1) DE68921803T2 (es)
DK (1) DK306890A (es)
ES (1) ES2070926T3 (es)
FI (1) FI906411A0 (es)
WO (1) WO1990000194A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US6509314B1 (en) * 1988-06-28 2003-01-21 The Burnham Institute Methods of preventing or reducing scarring with decorin or biglycan
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
WO1993009800A1 (en) * 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5650389A (en) * 1993-03-01 1997-07-22 University Of Alabama At Birmingham Research Foundation Methods for the inhibition of complement activation
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5567807A (en) * 1994-07-08 1996-10-22 La Jolla Cancer Research Foundation Processes for the purification of human recombinant decorin and the detection of guanidinium ions
EP1025205A2 (en) 1997-10-28 2000-08-09 President And Fellows Of Harvard College (in vitro) differentiation of vascular smooth muscle cells, methods and reagents related thereto
NZ522971A (en) * 2000-05-05 2005-02-25 Gtc Biotherapeutics Inc Transgenically produced decorin in the mammary gland of a transgenic animal
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
WO2003061587A2 (en) * 2002-01-22 2003-07-31 Genzyme Corporation USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
JP5128935B2 (ja) * 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
KR100747646B1 (ko) * 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
JP2006295872A (ja) * 2005-03-18 2006-10-26 Matsushita Electric Ind Co Ltd 機器固有鍵の生成方法、これを用いた機密情報処理機能を備えた機密情報ｌｓｉ、これを搭載したホスト機器、これに用いられる認証機能付き記録媒体、および認証機能を備えた記録媒体付き携帯端末
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
EP1998810A4 (en) 2006-03-13 2009-09-02 Univ Johns Hopkins INCREASE OF ENDOTHELIAL THROMBORESISTENTEN
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
MX2009003518A (es) * 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
US9053063B2 (en) 2007-02-21 2015-06-09 At&T Intellectual Property I, Lp Method and apparatus for authenticating a communication device
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
DK3117709T3 (en) 2010-03-12 2018-11-26 Genzyme Corp COMBINATION THERAPY FOR TREATMENT OF BREAST CANCER
EP2660314A4 (en) 2010-12-27 2014-09-03 Lsip Llc IPS CELLS AND METHOD FOR THEIR PRODUCTION
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
AU2014257267B2 (en) 2013-04-22 2017-03-16 Catalent Pharma Solutions, Llc Veterinary decorin compositions and use thereof
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624789B2 (en) * 1987-02-19 1992-06-25 Amgen, Inc. Purified platelet-derived growth factor and methods for purification thereof
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity

Also Published As

Publication number Publication date
DK306890D0 (da) 1990-12-28
CA1340112C (en) 1998-11-03
US5726149A (en) 1998-03-10
FI906411A0 (fi) 1990-12-27
JPH03503846A (ja) 1991-08-29
JP2887325B2 (ja) 1999-04-26
EP0349480A1 (en) 1990-01-03
ATE120235T1 (de) 1995-04-15
JP2003034651A (ja) 2003-02-07
WO1990000194A1 (en) 1990-01-11
DE68921803D1 (de) 1995-04-27
EP0349480B1 (en) 1995-03-22
AU3865389A (en) 1990-01-23
JPH09117278A (ja) 1997-05-06
DK306890A (da) 1990-12-28
AU633011B2 (en) 1993-01-21
US6046162A (en) 2000-04-04
DE68921803T2 (de) 1995-07-13

Similar Documents

Publication Publication Date Title
ES2070926T3 (es) Supresion de la proliferacion celular mediante decorin.
DE69032406D1 (de) Wundheilmittel enthaltend heparanase
GB2165087B (en) Improved operation of microbial fuel cells
ES2036192T3 (es) Derivados del acido (met)-acrilico, que contienen grupos uretano, de triciclo (5.2.1.0.2.6) decano.
ZA861653B (en) Phenyl carbamates
AU3969689A (en) Bio-reactor cell culture process
EP0353893A3 (en) Cell culture bioreactor
AU1621783A (en) Cell culture microcarriers
EP0297605A3 (en) Cell culture microcarriers
AU6138586A (en) Novel enzymes for degradation of lignin
DE59010334D1 (de) Wasserstoff/Sauerstoff-Brennstoffzelle
AU8138582A (en) Cooling of carbon fibre gasification vessel
JO1637B1 (en) Contrast media (oxygen saturation)
ZA917561B (en) Media for culture of mammalian cells
AU617059B2 (en) Monosulfactams
AU3318084A (en) Cell culture system
AU572608B2 (en) Cell culturing with gas sparging
AU580035B2 (en) Coking residuum in the presence of hydrogen donor
GB8520929D0 (en) Vessel for culturing cells
NO905610L (no) Undertrykkelse av celleproliferasjon ved hjelp av decorin.
AU2928284A (en) Replacement of damaged membranes in electrolytic cells
AU583978B2 (en) Fermentation of bacteria at high productivities
AU533610B2 (en) Carbon or graphite fibre electrode
GB8432385D0 (en) Plant cell suspension cultures
AU561330B2 (en) Liquefaction of coal with hydrogen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 349480

Country of ref document: ES